Humacyte, Inc. (HUMA)Healthcare | Biotechnology | Durham, United States | NasdaqGS
0.65 USD
-0.04
(-6.150%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.66 +0.01 (0.877%) ⇧ (Aug. 28, 2026, 7:36 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:52 a.m. EDT
The investment case for Humacyte is currently broken by a catastrophic multi-year decline and a complete lack of capital return. Over the last four years, the stock has erased more than 84% of its value, driven by a brutal collapse in the trailing twelve months where shares lost three-quarters of their worth. Despite a recent year-over-year gain, the asset remains trapped in a structural downtrend where the market has priced out the business entirely. Fundamentally, the company is bleeding cash with negative operating margins and no return on equity, while holding a precarious balance sheet with debt exceeding equity. There is no dividend to provide any cushion for investors. On the trading front, the options market screams caution; the sheer volume of put buying suggests traders are betting on further deterioration rather than a turnaround. With a beta of 2.47, this is a high-volatility trap where the odds favor continued erosion of capital until a fundamental pivot occurs. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.093608 |
| AutoTheta | 0.103932 |
| AutoETS | 0.104897 |
| AutoARIMA | 1.489839 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 0.49 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.196 |
| Excess Kurtosis | 0.82 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 213.941 |
| Revenue per Share | 0.011 |
| Market Cap | 180,596,544 |
| Forward P/E | -2.63 |
| Beta | 2.47 |
| Website | https://www.humacyte.com |
As of Aug. 22, 2026, 2:52 a.m. EDT: Speculators are overwhelmingly positioning for downside protection. Put open interest significantly exceeds call open interest across nearly all expirations, with deep out-of-the-money puts showing massive volume spikes relative to calls. While there is some call activity at strikes like $2.50 and $3.50, these represent a tiny fraction of the put volume, indicating a market consensus focused on survival rather than recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5410596 |
| Address1 | 2,525 East North Carolina Highway 54 |
| All Time High | 17.45 |
| All Time Low | 0.526 |
| Ask | 0.6502 |
| Ask Size | 1 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 11,203,940 |
| Average Daily Volume3 Month | 11,007,320 |
| Average Volume | 11,007,320 |
| Average Volume10Days | 11,203,940 |
| Beta | 2.47 |
| Bid | 0.5838 |
| Bid Size | 3 |
| Board Risk | 7 |
| Book Value | 0.052 |
| City | Durham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.6501 |
| Current Ratio | 6.207 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.6954 |
| Day Low | 0.6401 |
| Debt To Equity | 213.941 |
| Display Name | Humacyte |
| Earnings Call Timestamp End | 1,786,536,000 |
| Earnings Call Timestamp Start | 1,786,536,000 |
| Earnings Timestamp | 1,786,537,800 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -103,228,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.623 |
| Enterprise To Revenue | 79.007 |
| Enterprise Value | 167,573,552 |
| Eps Current Year | -0.4 |
| Eps Forward | -0.2475 |
| Eps Trailing Twelve Months | -0.49 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.69516 |
| Fifty Day Average Change | -0.04505998 |
| Fifty Day Average Change Percent | -0.06481958 |
| Fifty Two Week Change Percent | -54.10596 |
| Fifty Two Week High | 2.55 |
| Fifty Two Week High Change | -1.8999 |
| Fifty Two Week High Change Percent | -0.74505883 |
| Fifty Two Week Low | 0.526 |
| Fifty Two Week Low Change | 0.12409997 |
| Fifty Two Week Low Change Percent | 0.23593149 |
| Fifty Two Week Range | 0.526 - 2.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,606,833,000,000 |
| Float Shares | 251,023,924 |
| Forward Eps | -0.2475 |
| Forward P E | -2.6266665 |
| Free Cashflow | -58,393,248 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 184 |
| Fullday Change | -0.0426 |
| Fullday Change Percent | -6.14985 |
| Fullday Price | 0.6558 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -79,374,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.05605 |
| Held Percent Institutions | 0.26618 |
| Implied Shares Outstanding | 277,798,105 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina. |
| Long Name | Humacyte, Inc. |
| Market | us_market |
| Market Cap | 180,596,544 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_107706507 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -96,668,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 193,180,802 |
| Number Of Analyst Opinions | 5 |
| Open | 0.69 |
| Operating Cashflow | -97,193,000 |
| Operating Margins | -66.492615 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 919 313 9633 |
| Post Market Change | 0.005699992 |
| Post Market Change Percent | 0.876787 |
| Post Market Price | 0.6558 |
| Post Market Time | 1,787,960,213 |
| Previous Close | 0.6927 |
| Price Eps Current Year | -1.62525 |
| Price Hint | 4 |
| Price To Book | 12.501923 |
| Price To Sales Trailing12 Months | 85.14689 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.367 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.6 |
| Region | US |
| Regular Market Change | -0.0426 |
| Regular Market Change Percent | -6.14985 |
| Regular Market Day High | 0.6954 |
| Regular Market Day Low | 0.6401 |
| Regular Market Day Range | 0.6401 - 0.6954 |
| Regular Market Open | 0.69 |
| Regular Market Previous Close | 0.6927 |
| Regular Market Price | 0.6501 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 4,915,922 |
| Return On Assets | -0.49866 |
| Return On Equity | -5.47872 |
| Revenue Growth | 0.349 |
| Revenue Per Share | 0.011 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 277,798,105 |
| Shares Percent Shares Out | 0.115 |
| Shares Short | 31,939,257 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 32,283,805 |
| Short Name | Humacyte, Inc. |
| Short Percent Of Float | 0.1157 |
| Short Ratio | 4.7 |
| Source Interval | 15 |
| State | NC |
| Symbol | HUMA |
| Target High Price | 4.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 1.85 |
| Target Median Price | 1.25 |
| Total Cash | 79,903,000 |
| Total Cash Per Share | 0.288 |
| Total Debt | 66,880,000 |
| Total Revenue | 2,121,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.49 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.9587 |
| Two Hundred Day Average Change | -0.3086 |
| Two Hundred Day Average Change Percent | -0.32189423 |
| Type Disp | Equity |
| Volume | 4,915,922 |
| Website | https://www.humacyte.com |
| Zip | 27,713 |